VEGFA and breast cancer: We followed the approach and rationale of our recent study on the selection of a panel of circulating miRs in patient samples [22]: Six miRs were selected based on the following criteria in order of priority: (a) abundance of the miR: Measurable levels in the plasma before and after treatment; (b) references in the published literature that relate the respective miR to breast cancer and/or to FGF, VEGF or PDGF signaling, i.e. the pathways targeted by dovitinib; (c) detectable change relative to dovitinib treatment by at least threefold up or down.